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BACKGROUND:  The  pathophysiology  of  complex
regional  pain  syndrome  type  1  (CRPS  1)  is  still  a
matter  of  debate.  Peripheral  afferent,  efferent  and
central mechanisms are supposed. Based on clinical
signs and symptoms (e.g. oedema, local temperature
changes  and  chronic  pain)  local  inflammation  is
suspected.
Aim: To determine the involvement of neuropetides,
cytokines and eicosanoids  as locally  formed  media-
tors of inflammation.
Methods:  In  this  study,  nine  patients  with  proven
CRPS  1  were  included.  Disease  activity  and  impair-
ment was determined by means of a Visual Analogue
Scale, the McGill Pain Questionnaire, the difference in
volume and temperature between involved and unin-
volved extremities, and the reduction in active range
of motion  of the  involved  extremity.  Venous  blood
was sampled from and suction blisters made on the
involved  and  uninvolved  extremities  for  measure-
ment  of  cytokines  interleukin  (IL)-6,  IL-1b and
tumour  necrosis  factor-a (TNF-a ), the  neuropetides
NPY and CRGP, and prostaglandin E2.
Results: The patients included in this study did have a
moderate to serious disease activity and impairment.
In plasma, no changes of mediators of inflammation
were observed. In blister fluid, however, significantly
higher  levels  of  IL-6  and  TNF-a in  the  involved
extremity  were  observed  in  comparison  with  the
uninvolved extremity.
Conclusions: This is the first time that involvement of
mediators  of  inflammation  in  CRPS  1  has  been  so
clearly  and  directly  demonstrated. This observation
opens  new  approaches  for  the  succesful  use  and
development of immunosuppressives in CRPS 1.
Key words: Complex regional pain syndrome, Neurogenic
inflammation, Pain,  Oedema, Temperature, Neuropeptide,
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Introduction
Complex regional pain syndrome type 1 (CRPS1) is a
disease characterized by spontaneous pain, allodynia
and hyperalgesia. The symptoms are not limited to the
region of a single peripheral nerve and are generally
disproportional to the inciting event. There is (or has
been) evidence of oedema, disturbed blood flow, or
abnormal  sudomotor  activity  in  the  affected  limb.
CRPS  1  diagnosis  is  excluded  by  the  existence  of
conditions  that  would  otherwise  account  for  the
degree of pain and dysfunction.1 CRPS 1 is a major
cause of disability, with a reported incidence of about
10% after various fractures, an incidence of 7–35% in
Colles’ fracture and, in 10–26% of cases, there is no
precipitating factor.2The pathophysiology of CRPS 1
remains unclear. In our recently published review, we
summarized  studies  in  which  peripheral  afferent,
efferent and also central mechanisms may play a role.3
Based on various clinical aspects of CRPS 1, such as
oedema, local temperature changes and chronic pain,
we assumed a neurogenic inflammation. The involve-
ment of an activated immune system could implicate
the subsequent release of neuropeptides, cytokines or
eicosanoids, which, in turn, would lead to a complex
interaction  of  primary  and  secondary  generated
mediators of inflammation. Until now, measurement
of blood plasma levels at the site of CRPS 1 showed no
change  in  pro-inflammatory  and  anti-inflammatory
cytokines.4 However,  this  could  be  because  all
patients  presented  in  the  latter  study  had  a  mean
disease history of 10 years. Furthermore, it remains
questionable whether systemic cytokine levels with
or without in vitro stimulation by lipopolysaccharide
reflect local inflammation. Because there is evidence
that substance P induces the release of interleukin-1b
(IL-1b)  and  tumour  necrosis  factor-a (TNF-a)  in
human skin,5 studies should focus on local formation
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Mediators of Inflammation, 11, 47–51 (2002)of cytokines in CRPS 1. To test our hypothesis that
mediators of inflammation play a role in CRPS 1, we
applied the suction blister technique to determine the
presence of pro-inflammatory cytokines in involved
local tissue.
Subjects and methods
Patients
The  study  was  approved  by  the  medical  ethical
committee  of  the  University  Hospital  Rotterdam
(MECnr. 198.780/2001/24). All patients had to fulfil
the CRPS 1 criteria as described by Bruehl et al.6 and
all  gave infomed consent. Patients using  corticoste-
roids or other immunosuppressives were excluded. In
April  and  May  2001,  we  studied  nine  patients  (for
demographic data, see Table 1).
Registration of pain
The  intensity  of  pain  was  assessed by  means  of  a
visual  analogue  scale  (VAS)7 and  the  McGill  Pain
Questionnaire  Dutch  Language  Version  (MPQ-
DLV).8–10The VAS was recorded in millimetres and the
MPQ-DLV score was measured by counting the total
number of words chosen.
Temperature
Temperature  was  monitored  by  local  infrared  tem-
perature measurement using a tympanic probe ther-
mometer  (First Temp  Genius®;  Sherwood  Medical,
Crawley,  Sussex,  UK).11 Temperature was measured
on the dorsal aspect of the hand or foot in five points
on  a  standard  matrix.  Differences  in  temperature
were calculated as the mean difference of these five
points  of  measurement  between  the  involved  and
uninvolved sides.
Oedema
Difference  in  volume  between  the  involved  and
uninvolved extremity was assessed with a volumeter,
which measures the amount of water displaced by
the immersion of a body part.12,13 For hand volume
measurements, we used a container with a volume
of 15l and a crosswise bar 10cm from the bottom.
The web between digiti 2 and 3 was positioned over
the  horizontal bar.  For  foot  volume  measurements,
we used a container with a volume of 40l. The foot
was placed as flat as possible on the bottom of the
container,  the  overflow  was  collected and  the  vol-
ume determined with a weighing balance (accuracy
of 1g).
Mobility
The active range of motion (AROM) is defined as the
arc  of  motion  with  muscle  power  to  achieve  the
motion of a joint. In the upper extremity, the AROM
was  measured  for  the  dorsal/palmar  flexion  in  the
wrist,  and  for  the  flexion/extension  in  the  met-
acarpophalangeal and proximal interphalangeal joints
of  the  two  most  restricted  digits.14 In  the  lower
extremity, the AROM was measured for the flexion/
extension in the ankle. The position of the patient and
the  method of  measurement  were  standardized for
each  joint,  conforming  to  the American Society  of
Hand  Therapists  clinical  assessment  recommenda-
tions.15The extent of reduced AROM was determined
by intra-individual comparison with the total AROM.
The total AROM was measured in the involved and
uninvolved extremity. The AROM on the impaired side
(multiplied by 100) was divided by the AROM on the
impaired side; this resulted in a percentage. Each joint
was  given  points  for  the  percentage  of  normal
mobility: 1 point, ‡  95%; 2 points, 94–85%; 3 points,
84–65%;  4  points,  64–25%;  and  5  points,  <  25%
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Table 1. Demographic data
Sex (male/female) 1/8
Age (years) 50 (48–51)
Duration of CRPS 1 (months) 8 (4–12)
CRPS 1, hand/foot 7/2
CRPS 1, trauma (accident, fracture)/surgery 3/6
Smoking history 9
Medical history 1 patient, hypertension; 1 patient, NIDDM
Medication
Corticosteroids and/or immunosuppressives None
Non-steroidal anti inflammatory drugs 5 patients
Metoprolol 1 patient
Metformine, glibenclamide 1 patient
Blood chemistry No deviations from normal values
Blood haematology No deviations from normal values
Blood sedimentation (BSE) (mm/h) 9 (6–15)
White blood cells (´ 10
9/l) 5.7 (4.9–7.1)
Data are for the nine patients and are presented as median ± interquartile range.
BSE; CRPS 1, complex regional pain syndrome type 1; NIDDM, Non-insulin-dependent  diabetes mellitus.normal mobility.16The sum of points of the measured
joints was calculated.
Plasma collection.
Venous blood was obtained from both the involved
and  uninvolved  extremities  for  determination  of
haematological and blood chemistry parameters. In
the upper extremity, blood was collected via a vena
cubita; in the lower extremity, via the vena femoralis.
For measurement of plasma mediators of inflamma-
tion,  10ml  of  blood  anti-coagulated  with  0.15%
ethylenediamine  tetraacetic  acid  was  drawn  into
endotoxin-free vacutainers (Vacutainer Systems; Bec-
ton-Dickinson,  Plymouth,  UK)  and  centrifuged  for
10min  at  20°C  and  2800  ´ gmax.  Thereafter,  the
plasma was stored at –80°C until analysis.
Blisters
Blisters  were  induced  using  the  suction  tech-
nique.17,18 The  blisters  were  formed  on  both  the
involved  and  uninvolved  extermity:  on  the  upper
extremity  on  the  dorsal  side  of  the  hand  and  the
flexor side of the forearm, and on the lower extremity
on the dorsal side of the foot and the frontal or lateral
side of the lowerleg. We initially  applied a negative
pressure  of  300mmHg,  which  was  reduced  after
15min to 250mmHg and again, 15min later, reduced
to 200mmHg. This negative pressure was maintained
for 2–2.5h until seven blisters per site (each 6mm in
diameter)  had  emerged.  This  procedure  produced
approximately 300ml blister fluid per site by punc-
ture of the blister. All samples were stored at –80°C
until analysis.
Laboratory assays
Sample preparation
Undiluted plasma samples (100ml) were assayed for
cytokines IL-1b, interleukin-6 (IL-6) and  TNF-a without
prior sample preparation. Blister fluids were twofold
to  fourfold  diluted  in  assay  buffer  for  the  direct
measurement of cytokines. For the determination of
neuropeptides  CGRP  and  NPY,  400ml  of  undiluted
plasma  and  diluted  blister  fluid  was  applied  to  an
Oasis® HLB extraction cartridge (Waters Ass., Etten-
Leur, The Netherlands). According to the assay proto-
col, all samples were acidified with 1% trifluoroacetic
acid (TFA) and eluted with 60% acetonitrile in 1% TFA
in 39% distilled water. The eluant was evaporated to
dryness  in  a  centrifugal  concentrator  (SpeedVac,
Savant,  Switzerland)  and  the  dried  extract  recon-
stituted with peptide assay buffer. In parallel, sample
elution  of  prostaglandin  E2 from  the  Oasis®  HLB
column was completed by the subsequent elution of
100% of methanol. Evaporation and reconstitution was
similar to the procedure followed for neuropeptides.
Immunoassays
For  the  determination  of  cytokines,  assays  were
performed  following  the  manufacturer’s  protocol
(PeliKine-compact™ human ELISA kits; CLB, Amster-
dam, The Netherlands). The standard curve ranges and
detection  limits,  respectively,  were:  for  IL-1b,
0–300pg/ml and 0.2pg/ml; for IL-6, 0–450pg/ml and
0.3pg/ml; and for TNF-a, 0–1000pg/ml and 1pg/ml.
The  peptide  enzyme  immunoassays  used  for  the
determination of CGRP and NPY were EIAH-6006 and
EIAH-7180, respectively (Peninsula Laboratories Inc.,
Belmont, CA, USA). Standard curve ranges from 0 to
10ng/ml  were  included.  The  minimal  detectable
concentration was 0.06ng/ml.
Prostaglandin E2 was determined by enzyme immu-
noassay (Biotrak EIA,  RPN 222;  Pharmacia Biotech,
Amersham, UK). The standard curve range was 0 to
6.4ng/ml.
All  assays  were  performed  in  96-well  microtitre
plates. The  absorbance  per  well  was  measured  at
450nm  with  a  Medgenix  EASIA  reader  (Fleurus,
Belgium).  Sample  concentrations  were  calculated
using the appropriate standard calibration lines and
the Softmax® software of the reader.
Statistical analysis
First,  data were analysed for linearity.  If  non-linear,
frequencies  were  described  as  median  and  inter-
quartile  ranges. Correlation was measured with the
Spearman’ test, and the difference in parameters was
tested with the Wilcoxon rank sum test. Significance
was accepted with p < 0.05.
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Table 2. Signs and symptoms of impairment
Visual Analogue Scale (0–100mm, no pain–most pain) 49 (30–52)
McGill Pain Questionnare (number of counted words that describe pain) 11 (11–12)
Difference in temperature between involved and uninvolved sides (DT, (C) –0.24 (–0.02 to –0.9)
Difference in volume between involved and uninvolved sides (DV, % volume of uninvolved
extremity)
2.9 (1.4–4.5)
Active range of motion (sum of numbers that express the percentage of normal mobility
extremity; 5–55, normal mobility-most abnormal)
18 (11–20)
Data are for the nine patients and are presented as median ± interquartile range.Results
The clinical signs and symptoms of impairment from
the  patients  are described in  terms of median  and
interquartile VAS,  number  of  words counted in  the
McGill  Pain  Questionnaire,  differences  in  tempera-
ture,  differences  in  percentage  volume  and AROM
classified as a number. The results are presented in
Table 2.
Data on cytokines, neuropetides and prostaglandin
E2 levels in plasma and blister fluid in the involved
and uninvolved extremities are presented in Table 3.
There was no correlation between the clinical signs
and symptoms of impairment and the mediators of
inflammation.
There  was  a  significant  difference  (p <  0.05,
Wilcoxon  rank  sum  test)  in  IL-6  and TNF-a levels
between  blisters  on  the  involved  and  uninvolved
extremities. There was no difference in IL-1b, NPY,
CGRP and prostaglandin E2 levels between blisters on
the involved and uninvolved extremities. There is no
significant difference between any measured value in
plasma from involved and uninvolved extremities (see
Table 3).
Discussion
To our knowledge, this is the first time that increased
local levels of the pro-inflammatory cytokines IL-6 and
TNF-a have been detected locally in CRPS 1.
Until now, the involvement of a neurogenic inflam-
mation  remains  debatable.  Results  of  a  large  pro-
spective  study  suggested  that  the  early  signs  and
symptoms of  CRPS 1  resembled regional inflamma-
tion,2 and a scintigraphic study  on CRPS 1 demon-
strated vascular leakage of macromolecules.19 These
latter  results  also  suggest  the  presence  of  local
inflammation. A 31P nuclear resonance spectroscopy
study showed impairment of high-energy phosphate
metabolism in muscles of patients with CRPS 1; this
may have been caused by cellular hypoxia or dimin-
ished oxygen utilization, which is classically seen in
inflammation.20 Substance P and CRPG are neurope-
tides that play an important role in oedema formation
and inflammation.21 In blood sampled from patients
with CRPS 1, bradykinin, NPY, CGRP and vasoactive
intestinal peptide were considerably increased com-
pared with healthy volunteers, whereas substance P,
neurokinin A  and  B  were  unchanged.22Infusion  of
substance P in the CRPS 1 extremity has been shown
to  potentiate  signs  and  symptoms.23 Depletion  of
substance P from primary afferent neurons by topical
application of capsaicin effectively diminished signs
and  symptoms  in  CRPS  1  and  comparable  dis-
eases.24,25 In  contrast,  another  study  showed  sig-
nificantly lower levels of NPY in blood drawn from
CRPS  1  extremities  compared with  the  uninvolved
sides.26,27 CGRP, substance P and NPY were unchan-
ged in samples of hyperalgesic skin from dorsal hand
and foot.28
In our study, there was no paired increase in local
neuropeptide  formation,  as  measured  by  NPY  and
CGRP. Although substance P can induce the release of
IL-1a and TNF-a in  human  skin,5 our  findings  of
increased pro-inflammatory IL-6 and TNF-a in blister
fluids  may  not necessarily be the direct result  of  a
primary neurogenic inflammation. In view of the lack
of  a  clear  contribution  of  neuropeptides,  in  our
patients a late phase reaction could be considered in
which  not  only  mononuclear  cells,  but  also  poly-
morphonuclear cells could be involved. Therefore, a
wide  range  of  immunocompetent  cells,  such  as
activated  T  lymphocytes,  monocytes  and  macro-
phages, and skin resident cells, such as keratinocytes,
fibroblasts,  endothelial  cells  and  mast  cells,  could
contribute to this complex interplay of mediators of
inflammation formed at the site of the CRPS 1. In our
patients, the levels of cytokines found in blister fluid
were comparable with those seen in psoriasis where
cytokines clearly correlate with psoriasis severity.29,30
Capsaicin-treated normal skin showed minor, but not
significant,  effects  on  the  diminished  release  of
inflammatory mediators.31 On the contrary, pharma-
cological intervention by betamethasone or salicylic
acid  showed  a  clear  disease  improvement  and  sig-
nificant decreases in cytokine levels in blister fluid.32
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Table 3. Mediators of inflammation, and levels in plasma and blister fluid in the involved and uninvolved extremities
Plasma
Involved side Uninvolved side
Blister
Involved side Uninvolved side
IL-6 (pg/ml) 0.8 (0.6–1.4) 0.8 (0.6–1.4) 54 (19–68)* 17 (4.9–20)
IL-1b (pg/ml) 1.5 (0.4–28) 1.1 (0.5–24) 1.7 (1.0–1.8) 1.7 (1.5–1.9)
TNF-a (pg/ml) 4.6 (2.2–17.6) 2.3 (0.8–14.6) 18 (11–37)* 7 (4.7–8.2)
NPY (ng/ml) 0.4 (0.3–0.5) 0.4 (0.3–0.4) 1.7 (1.1–2.3) 1.9 (1.5–2.3)
CGRP (ng/ml) 0.2 (0.2–0.3) 0.4 (0.2–0.4) 2.8 (1.7–2.9) 3.4 (1.8–4)
PGE2 (ng/ml) 6.1 (5.6–7) 5.8 (5.5–6.6) 23 (14–29) 27 (21–28)
Data are for the nine patients and are presented as median ± interquartile range.
IL, Interleukin; TNF-a, tumor necrosis factor-a; PGE2, prostaglandin E2.
*Wilcoxon rank sum test, p < 0.05.Generally, involvement of inflammatory mediators
in a disease may be considered when generation at
the site of injury can be confirmed. Futhermore, local
injection  of  these  mediators  should  provoke  or
increase clinical signs and symptoms. Treatment with
specific antagonists or synthase inhibitors of inflam-
matory  mediators  that  are  involved  should  have
beneficial effects on disease activity.
Until now, evidence that inflammatory mediators
are  involved  has  only  indirectly  been  shown  by
injection of substance P, which results in a deteriora-
tion of the signs and symptoms.
Our data indicate, in a direct way, that inflamma-
tion plays an important role in CRPS 1. The challenge
now  is  to  investigate  the  entire  time-dependent
cascade  of  inflammatory  mediators  that  could  be
involved in CRPS 1 and then develop antagonists or
synthesis  inhibitors  that are  beneficial  in  the  treat-
ment of this disabling disease.
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